ACTION HIV: A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

What this Trial Is About

Researchers are conducting an observational study to understand prognostic and predictive factors affecting patients with anal squamous cell carcinoma (CCA), both with and without HIV infection. The study seeks to describe patient profiles worldwide, including factors such as CD4 counts, duration of HIV infection, viral load, AIDS diagnosis, geographic treatment regions, clinical staging, medication interactions, comorbidities, use and duration of highly active antiretroviral therapy (HAART), and radiotherapy types. It aims to compare clinical outcomes between patients living with HIV and those without. Participants include patients diagnosed with anal squamous cell carcinoma, with or without HIV infection. The study groups are divided based on HIV status. Data collected will reflect real-world treatment modalities, including conventional 3D radiotherapy versus Intensity Modulated Radiotherapy (IMRT), and responses to specific chemotherapy regimens. There are no interventional treatments assigned by the study, as this is an observational record. Participants will be followed to assess key outcomes such as median disease-free survival over three years, complete clinical response at six months, and overall survival from treatment start to death from any cause within three years. Researchers will gather data on treatment details, clinical staging, medication use, and other health factors. The study aims to provide comprehensive insights into how HIV status and related factors influence anal cancer treatment outcomes and survival over time.

A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection